keyword
MENU ▼
Read by QxMD icon Read
search

Colorectal liver secondaries

keyword
https://www.readbyqxmd.com/read/27920414/morbidity-and-mortality-and-predictors-of-outcome-following-hepatectomy-at-a-saudi-tertiary-care-center
#1
Faisal Al-Alem, Rafif Essam Mattar, Ola Abdelmonem Fadl, Abdulsalam Alsharabi, Faisal Al-Saif, Mazen Hassanain
BACKGROUND: Hepatic resection is a major surgical procedure. Data on outcomes of hepatectomy in Saudi Arabia are scarce. OBJECTIVE: To measure morbidity and mortality and assess predictors of outcome after hepatectomy. DESIGN: Descriptive study. SETTING: Tertiary care center in Saudi Arabia with well established hepatobiliary surgery unit. PATIENTS AND METHODS: All patients undergoing liver resection in our institute during 2006-2014...
November 2016: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/27899088/alternative-splicing-of-estrogen-receptor-alpha-in-hepatocellular-carcinoma
#2
Jian Zhang, Jianwei Ren, Jiamin Wei, Charing C N Chong, Dongjie Yang, Yulong He, George G Chen, Paul B S Lai
BACKGROUND: The role of estrogen receptor alpha (ERa), estrogen receptor beta (ERb) and ERa36 signaling in hepatocellular carcinoma (HCC) is not fully addressed. METHODS: In this study, three cohorts were included: (i) primary HCC patients (N = 76, cohort P), (ii) colorectal liver metastasis (mCRC) (N = 32, cohort S), and (iii) HCC from The Cancer Genome Atlas (TCGA) (N = 121). The levels of ERa36 and wtER36 were measured and their correlation with clinicopathologic features was determined...
November 30, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27863195/prediagnosis-body-mass-index-and-risk-of-secondary-primary-cancer-in-male-cancer-survivors-a-large-cohort-study
#3
Sang Min Park, Young Ho Yun, Young Ae Kim, Minkyung Jo, Young-Joo Won, Joung Hwan Back, Eun-Sook Lee
Purpose Male cancer survivors have a higher risk of cancer than the general population, which might be caused by an increased prevalence of obesity or susceptibility to obesity-related carcinogenesis. We assessed the effects of obesity before the diagnosis of a first cancer on the development of secondary primary cancers (SPCs). Methods The study population consisted of 239,615 Korean male cancer survivors between January 2003 and December 2010. Incident SPCs were assessed throughout follow-up until December 2011...
December 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27848159/effect-of-chemotherapy-on-the-impact-of-fdg-pet-ct-in-selection-of-patients-for-surgical-resection-of-colorectal-liver-metastases-single-center-analysis-of-pet-cam-randomized-trial
#4
Ur Metser, Jaydeep Halankar, Deanna Langer, Ravi Mohan, Douglas Hussey, Moshonov Hadas, Shlomit Tamir
: The largest randomized controlled trial (RCT) on the effect of FDG-PET on surgical management for metastatic colorectal adenocarcinoma to liver ("PET-CAM") reported only a modest change in surgical management (8%). PURPOSE: To explore the relationship between prior chemotherapy and detection of metastatic disease on PET in patients from PET-CAM. Secondary aim: to determine whether centralized imaging interpretation could have impacted trial results. METHODS: The study included 120 patients from a single institution...
November 15, 2016: Annals of Nuclear Medicine
https://www.readbyqxmd.com/read/27842595/long-term-survival-in-pseudo-meigs-syndrome-caused-by-ovarian-metastases-from-colon-cancer
#5
Yosuke Tajima, Hitoshi Kameyama, Saki Yamada, Ryoma Yagi, Masato Nakano, Masayuki Nagahashi, Yoshifumi Shimada, Jun Sakata, Takashi Kobayashi, Hajime Umezu, Toshifumi Wakai
BACKGROUND: Meigs' syndrome is defined as the co-existence of benign ovarian fibroma or fibroma-like tumor, ascites, and pleural effusion. In contrast, pseudo-Meigs' syndrome is defined as the co-existence of other ovarian or pelvic tumors, ascites, and pleural effusion. In Meigs' and pseudo-Meigs' syndromes, ascites and pleural effusion resolve promptly after the complete resection of the ovarian or pelvic tumor(s). Secondary ovarian tumors from colorectal gastrointestinal metastases rarely cause pseudo-Meigs' syndrome; only 11 cases of pseudo-Meigs' syndrome secondary to colorectal cancers have been reported in the literature...
November 14, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27798773/chemosaturation-percutaneous-hepatic-perfusion-a-systematic-review
#6
REVIEW
Arndt Vogel, Sanjay Gupta, Martin Zeile, Rebecca von Haken, Roland Brüning, Gösta Lotz, Alexander Vahrmeijer, Thomas Vogl, Frank Wacker
: The Hepatic CHEMOSAT(®) Delivery System is an innovative medical device for the treatment of patients with unresectable primary liver tumors or unresectable hepatic metastases from solid organ malignancies. This system is used to perform chemosaturation percutaneous hepatic perfusion (CS-PHP), a procedure in which a high dose of the chemotherapeutic agent melphalan is delivered directly to the liver while limiting systemic exposure. In a clinical trial program, CS-PHP with melphalan significantly improved hepatic progression-free survival in patients with unresectable hepatic metastases from ocular or cutaneous melanoma...
October 31, 2016: Advances in Therapy
https://www.readbyqxmd.com/read/27782851/surefire-infusion-system-versus-standard-microcatheter-use-during-holmium-166-radioembolization-study-protocol-for-a-randomized-controlled-trial
#7
Andor F van den Hoven, Jip F Prince, Rutger C G Bruijnen, Helena M Verkooijen, Gerard C Krijger, Marnix G E H Lam, Maurice A A J van den Bosch
BACKGROUND: An anti-reflux catheter (ARC) may increase the tumor absorbed dose during radioembolization (RE) by elimination of particle reflux and its effects on hemodynamics. Since the catheter is fixed in a centro-luminal position, it may also increase the predictive accuracy of a scout dose administration before treatment. The purpose of the SIM trial is to compare the effects of ARC use during RE with holmium-166 ((166)Ho) microspheres in patients with colorectal liver metastases (CRLM), with the use of a standard end-hole microcatheter...
October 25, 2016: Trials
https://www.readbyqxmd.com/read/27782839/secondary-metastasis-in-the-lymph-node-of-the-bowel-invaded-by-colon-cancer-a-report-of-three-cases
#8
Aki Takiyama, Hiroaki Nozawa, Soichiro Ishihara, Hirotoshi Takiyama, Koji Murono, Koji Yasuda, Kensuke Otani, Takeshi Nishikawa, Toshiaki Tanaka, Tomomichi Kiyomatsu, Kazushige Kawai, Keisuke Hata, Toshiaki Watanabe
BACKGROUND: Secondary metastasis to regional lymph nodes for adjacent bowel invaded by colorectal cancers (CRCs) has not been extensively reviewed. We herein present three such cases. CASE PRESENTATION: The first case is a cancer involving the cecum and sigmoid colon, and its primary site could not be determined even by pathological evaluation. Nodal involvement was revealed both in the mesocolon of the cecum and sigmoid. The second and third cases are a sigmoid colon cancer invading the jejunum and an ascending colon cancer invading the jejunum, respectively...
October 26, 2016: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27750238/us-us-fusion-imaging-in-radiofrequency-ablation-for-liver-metastases
#9
Yasunori Minami, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Tadaaki Arizumi, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Hiroshi Ida, Kazuomi Ueshima, Naoshi Nishida, Masatoshi Kudo
OBJECTIVE: Radiofrequency ablation (RFA) induces gas bubbles in ablation zones, and the ablative margin cannot be evaluated accurately on ultrasound (US) during and immediately after RFA. This study assessed the usefulness of US-US fusion imaging to visualize the ablative margin of RFA for liver metastasis. METHODS: RFA guided by US-US fusion imaging was performed on 12 targeted tumors in 10 patients. Secondary hepatic malignancies included patients with colorectal cancer (n = 4), breast cancer (n = 2), lung cancer (n = 1), gastrointestinal stromal tumor (n = 1), pancreatic neuroendocrine tumor (n = 1), and adrenocortical carcinoma (n = 1)...
2016: Digestive Diseases
https://www.readbyqxmd.com/read/27735065/spironolactone-use-and-risk-of-incident-cancers-a-retrospective-matched-cohort-study
#10
Isla S Mackenzie, Steven V Morant, Li Wei, Alastair M Thompson, Thomas M MacDonald
AIMS: Spironolactone is widely used to treat heart failure, hypertension and liver disease with increased usage in recent years. Spironolactone has endocrine effects that could influence cancer risks and historical reports suggest possible links with increased risk of certain types of cancer. The aim of this study was to assess the effect of spironolactone exposure on cancer incidence. METHODS: A pharmacoepidemiological propensity score-matched cohort study was performed to assess the effect of spironolactone exposure on cancer incidence...
October 13, 2016: British Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/27733753/unresectable-liver-metastases-in-colorectal-cancer-review-of-current-strategies
#11
Benjamin Sueur, Olivier Pellerin, Thibault Voron, Anne L Pointet, Julien Taieb, Simon Pernot
The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset. Potentially resectable patients should be distinguished from clearly unresectable patients. In defining resectability, it is important to take into account both anatomic characteristics and patient characteristic (comorbidities, symptoms, age). According to this evaluation, treatment should be tailored to each patient. The most widely accepted standard is doublet cytotoxic regimen plus biotherapy (anti-EGFR or anti- VEGF antibodies according to RAS status, but some patients could benefit from an intensified regimen, as triplet chemotherapy +/- bevacizumab, or intraarterial treatments (hepatic arterial infusion, radioembolization or chemoembolization), in order to allow resectability...
October 12, 2016: Minerva Chirurgica
https://www.readbyqxmd.com/read/27676291/mapping-eortc-qlq-c30-to-eq-5d-3l-in-patients-with-colorectal-cancer
#12
Emily-Ruth Marriott, Guy van Hazel, Peter Gibbs, Anthony J Hatswell
AIMS: The primary aim of this study was to perform a mapping of the EORTC-QLQ-C30 scores to EQ-5D-3L for the SIRFLOX study; a large dataset of patients with previously untreated liver-only or liver-dominant metastatic colorectal cancer (mCRC). A secondary aim was to compare the predictive validity of existing mappings from EORTC-QLQ-C30 to EQ-5D-3L conducted in other cancers. METHODS AND MATERIALS: Questionnaires (completed within 529 patients) were used in a linear mixed regression to model EQ-5D-3L utility values (scored using the UK tariff) as a function of the five function scores, nine symptom scores, and the global score from the EORTC-QLQ-C30 questionnaire...
October 13, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27611010/partial-splenic-embolization-to-permit-continuation-of-systemic-chemotherapy
#13
Jose Hugo M Luz, Paula M Luz, Edson Marchiori, Leonardo A Rodrigues, Hugo R Gouveia, Henrique S Martin, Igor M Faria, Roberto R Souza, Roberto de Almeida Gil, Alexandre de M Palladino, Karina B Pimenta, Henrique S de Souza
Systemic chemotherapy treatments, commonly those that comprise oxaliplatin, have been linked to the appearance of distinctive liver lesions that evolves to portal hypertension, spleen enlargement, platelets sequestration, and thrombocytopenia. This outcome can interrupt treatment or force dosage reduction, decreasing efficiency of cancer therapy. We conducted a prospective phase II study for the evaluation of partial splenic embolization in patients with thrombocytopenia that impeded systemic chemotherapy continuation...
September 9, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27588959/adjuvant-oral-uracil-tegafur-with-leucovorin-for-colorectal-cancer-liver-metastases-a-randomized-controlled-trial
#14
Kiyoshi Hasegawa, Akio Saiura, Tadatoshi Takayama, Shinichi Miyagawa, Junji Yamamoto, Masayoshi Ijichi, Masanori Teruya, Fuyo Yoshimi, Seiji Kawasaki, Hiroto Koyama, Masaru Oba, Michiro Takahashi, Nobuyuki Mizunuma, Yutaka Matsuyama, Toshiaki Watanabe, Masatoshi Makuuchi, Norihiro Kokudo
BACKGROUND: The high recurrence rate after surgery for colorectal cancer liver metastasis (CLM) remains a crucial problem. The aim of this trial was to evaluate the efficacy of adjuvant therapy with uracil-tegafur and leucovorin (UFT/LV). METHODS: In the multicenter, open-label, phase III trial, patients undergoing curative resection of CLM were randomly assigned in a 1:1 ratio to either the UFT/LV group or surgery alone group. The UFT/LV group orally received 5 cycles of adjuvant UFT/LV (UFT 300mg/m2 and LV 75mg/day for 28 days followed by a 7-day rest per cycle)...
2016: PloS One
https://www.readbyqxmd.com/read/27573524/outcomes-of-rehepatectomy-for-colorectal-liver-metastases-a-contemporary-multi-institutional-analysis-from-the-french-surgical-association-database
#15
Julie Hallet, Antonio Sa Cunha, Rene Adam, Diane Goéré, Daniel Azoulay, Jean-Yves Mabrut, Fabrice Muscari, Christophe Laurent, Francis Navarro, Patrick Pessaux
BACKGROUND: Recurrence remains frequent after curative-intent hepatectomy for colorectal liver metastases (CRLM). We sought to define short- and long-term outcomes, and identify prehepatectomy factors associated with survival, following rehepatectomy (RH) for recurrence. METHODS: We conducted a multi-institutional cohort study of hepatectomy for CRLM over 2006-2013. Second-stage resections were excluded. Primary outcomes were overall survival (OS) and recurrence-free survival (RFS) assessed using Kaplan-Meier methods...
August 29, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27566258/response-rates-of-hepatic-arterial-infusion-pump-therapy-in-patients-with-metastatic-colorectal-cancer-liver-metastases-refractory-to-all-standard-chemotherapies
#16
Andrea Cercek, Taryn M Boucher, Jill S Gluskin, Ariel Aguiló, Joanne F Chou, Louise C Connell, Marinela Capanu, Diane Reidy-Lagunes, Michael D'Angelica, Nancy E Kemeny
BACKGROUND AND OBJECTIVES: To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments. METHODS: A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies. RESULTS: One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents)...
November 2016: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27566041/from-bench-to-bedside-clinical-implications-of-kras-status-in-patients-with-colorectal-liver-metastasis
#17
REVIEW
Nikolaos Andreatos, Sean Ronnekleiv-Kelly, Georgios A Margonis, Kazunari Sasaki, Faiz Gani, Neda Amini, Ana Wilson, Timothy M Pawlik
INTRODUCTION: While the role of KRAS in the molecular genetics of colorectal cancer has been studied extensively, its prognostic impact in colorectal liver metastases (CRLM) has only recently been examined. This review aimed to summarize currently reported findings on the clinical implications of KRAS mutant (mut-KRAS) status for patients with CRLM. MATERIALS AND METHODS: The Pubmed database was searched for relevant articles published from 01/01/2010 to 02/01/2016...
September 2016: Surgical Oncology
https://www.readbyqxmd.com/read/27565426/a-preliminary-randomised-controlled-study-of-short-term-antrodia-cinnamomea-treatment-combined-with-chemotherapy-for-patients-with-advanced-cancer
#18
Ming-Yen Tsai, Yu-Chiang Hung, Yen-Hao Chen, Yung-Hsiang Chen, Yu-Chuen Huang, Chao-Wei Kao, Yu-Li Su, Hsien-Hsueh Elley Chiu, Kun-Ming Rau
BACKGROUND: Antrodia cinnamomea (AC) is a popular medicinal mushroom in Taiwan that has been widely used for treatment of various cancers. Few clinical studies have reported its application and efficiency in therapeutic chemotherapy strategies. We performed a double-blind, randomized clinical study to investigate whether AC given for 30 days had acceptable safety and efficacy in advanced cancer patients receiving chemotherapy. METHODS: Patients with advanced and/or metastatic adenocarcinoma, performance status (PS) 0-2, and adequate organ function who had previously been treated with standard chemotherapy were randomly assigned to receive routine chemotherapy regimens with AC (20 ml twice daily) orally for 30 days or placebo...
August 26, 2016: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/27561844/paragon-ii-a-single-arm-multicentre-phase-ii-study-of-neoadjuvant-therapy-using-irinotecan-bead-in-patients-with-resectable-liver-metastases-from-colorectal-cancer
#19
R P Jones, H Z Malik, S W Fenwick, M Terlizzo, E O'Grady, S Stremitzer, T Gruenberger, M Rees, G Plant, J Figueras, M Albiol, R Adam, S Awad, G J Poston
PURPOSE: Perioperative chemotherapy confers a 3-year progression free survival advantage following resection of colorectal liver metastases (CRLM), but is associated with significant toxicity. Chemoembolisation using drug eluting PVA microspheres loaded with irinotecan (DEBIRI) allows sustained delivery of drug directly to tumour, maximising response whilst minimising systemic exposure. This phase II single arm study examined the safety and feasibility of DEBIRI before resection of CRLM...
August 10, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27556427/-technique-of-mesohepatectomy
#20
T Huber, F Bartsch, H Lang
In patients with primary or secondary malignant central liver tumours, the standard surgical procedure is extended left or right hemihepatectomy. Since extended resections are associated with increased morbidity and mortality and a loss of a large amount of functional liver parenchyma, central liver resection or mesohepatectomy (resection of segments 4a/4b, 5 and 8) with or without the resection of segment 1 is an alternative procedure, although technically demanding and not widely used so far. Resection margins are to the right of the falciform ligament and at the border between segments 5/6 and 7/8, which can be difficult to differentiate...
August 2016: Zentralblatt Für Chirurgie
keyword
keyword
61684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"